MPS

Inventiva Announces Poster Presentation on a Promising Biomarker for MPS VI at the 15th International Symposium on MPS and Related Diseases

26 July 2018

Inventiva announces positive outcomes of biomarker study measuring intracellular GAGs in leukocytes from MPS VI patients

26 February 2018

Inventiva Announces Enrollment of First Patient into Its Odiparcil Phase IIa Trial (iMProveS) for MPS VI

3 January 2018

Inventiva’s Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the European Medicines Agency

29 August 2017

Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the FDA

10 August 2017

Inventiva Announces New Compelling Data on Odiparcil/IVA336 to be Presented at MPS Society National Conference

29 June 2017

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Functional

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

Cookie	Duration	Description
pll_language	1 year	The pll _language cookie is used by Polylang to remember the language selected by the user when returning to the website, and also to get the language information when not available in another way.

Performance

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_gat_gtag_UA_173436417_1	1 Jour/s	Ces cookies sont utilisés pour collecter des informations sur la façon dont les visiteurs utilisent notre site Web. Ceci est unique au propriétaire du site Web
_gat_gtag_UA_55628332_1	1 minute	Set by Google to distinguish users.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
CONSENT	2 years	YouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.

Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.

Cookie	Duration	Description
VISITOR_INFO1_LIVE	5 months 27 days	A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
YSC	session	YSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages.
yt-remote-connected-devices	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt-remote-device-id	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.

Others

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

Cookie	Duration	Description
43410	session	No description available.
43411	session	No description
bm_mi	session	No description available.
DrupalVisitorMobile	session	No description available.
GZIP	5 years	No description available.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
ak_bmsc	2 hours	This cookie is used by Akamai to optimize site security by distinguishing between humans and bots
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
JSESSIONID	session	The JSESSIONID cookie is used by New Relic to store a session identifier so that New Relic can monitor session counts for an application.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Inventiva Announces New Compelling Data on Odiparcil/IVA336 to be Presented at MPS Society National Conference

MPS

Inventiva to Present Corporate Overview at the Cowen and Company 39th Annual Health Care Conference

The FDA Grants Rare Pediatric Disease Designation to Odiparcil for the Treatment of MPS VI

Inventiva Announces Poster Presentation on a Promising Biomarker for MPS VI at the 15th International Symposium on MPS and Related Diseases

Inventiva announces positive outcomes of biomarker study measuring intracellular GAGs in leukocytes from MPS VI patients

Inventiva Announces Enrollment of First Patient into Its Odiparcil Phase IIa Trial (iMProveS) for MPS VI

Inventiva’s Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the European Medicines Agency

Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the FDA

Inventiva Announces New Compelling Data on Odiparcil/IVA336 to be Presented at MPS Society National Conference

About Inventiva